Live Breaking News & Updates on Patient Rep

Stay updated with breaking news from Patient rep. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Significant Fatigue Common in Adult Patients with Sickle Cell Disease

A lower FACIT-Fatigue score, indicating higher fatigue was independently associated with female sex, a high BMI, a high stress level, and poor sleep quality. ....

Value Health , Lancet Haematology Commission , Functional Assessment , Chronic Illness Therapy , Lancet Haematology , Population Norms , Chronic Illness Therapy Fatigue , Patient Rep ,

Empowering Advanced Practice Providers to Adopt Routine Screening for Tardive Dyskinesia

Tardive dyskinesia (TD) is an involuntary movement disorder associated with prolonged use of dopamine receptor blocking agents (DRBAs) that can range in severity and presentation and can impact social, emotional, and functional components of daily life. There are treatments that can effectively manage TD, but first it needs to be recognized and accurately diagnosed. ....

United States , San Diego , Amy Lacouture , Linda Trinh , Goodman Gilman , Psychopharmacology Research Branch , Neurocrine Biosciences Inc , Mental Health Administration , National Institute Of Mental Health , Mcgraw Hill , Drug Administration , Division Of Extramural Research Programs , Abnormal Involuntary Movement Scale , American Psychiatric Association , Public Health Service , Society Of Biological Psychiatry Annual Meeting , Neuroscience Education Institute Congress , Neurocrine Biosciences , Increase Routine , Differential Diagnosis , Important Safety Information , Boxed Warning , Increased Vigilance Among Advanced Practice , Neuroleptic Malignant Syndrome , Prescribing Information , Spec Issue ,

Camzyos®▼(mavacamten) recommended for use on the NHS as an add-on treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy

Camzyos®▼(mavacamten) recommended for use on the NHS as an add-on treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)Mavacamten has been recommended by the National Institute for Health and Care Excellence (NICE), as an add-on to individually optimised standard care, for t. ....

United Kingdom , Northern Ireland , United Kingdom General , Great Britain , Republic Of Ireland , Sunil Nair , Bristol Myers Squibb , Joel Rose , Scottish Medicines Consortium , National Health Service , British Heart Foundation , Norwich University Hospitals , National Centre For Pharmacoeconomics , Northern Ireland Department Of Health , National Institute For Health , Regulatory Agency , York Heart Association , European Commission , National Institute , Care Excellence , New York Heart Association , Final Guidance , Consultant Cardiologist , Chief Executive Officer , Cardiomyopathy United Kingdom , Bristol Myers ,